BackTable Urology

Ep. 64 Management of BCG-Refractory NMIBC with Dr. Timothy Clinton and Dr. Eugene Pietzak

09 Nov 2022

Audio

Description

In this episode of BackTable Urology, Dr. Aditya Bagrodia speaks with two fellow urologic oncologists, Dr. Timothy Clinton (Brigham and Women’s Hospital) and Dr. Eugene Pietzak (Memorial Sloan Kettering), about the management of BCG-refractory non muscle-invasive bladder cancer. --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn AMA PRA Category 1 CMEs: https://earnc.me/h8YiBe --- SHOW NOTES First, the doctors define BCG-refractory cancer from the clinical and FDA viewpoint. They emphasize the importance of determining the difference between BCG-resistant cancer and residual tumor from the primary resection. Blue light cystoscopy can help in confirming that the original tumor was totally resected. The doctors warn that although the initial response to BCG may be promising, there is still a chance of cancer recurrence. The success rate of BCG depends on the patient and tumor characteristics. Next, they discuss BCG-intolerant patients. BCG has many side effects such as frequency and urgency symptoms and bladder spasms. Some patients will have a systemic immune response resulting in flu-like symptoms. However, most of these side effects are self-limiting and should resolve after the induction course. They also discuss how to deal with the current BCG shortage. They first prioritize starting an induction course and view the maintenance course as a secondary priority. An erythematous and inflamed bladder can either be a result of BCG cystitis or a carcinoma in situ (CIS). The doctors agree that if the bladder is inflamed and the patient has a positive cytology, they would obtain a bladder biopsy to look for recurrent high-grade cancer. If the biopsy is positive, they would start a second induction course of BCG and introduce another form of therapy, like intravesical gemcitabine or an immune checkpoint modulator. If the bladder is inflamed and the patient has a negative cytology or a negative biopsy, they would continue with a BCG maintenance course and follow up. Cystectomy is a curative option for BCG-refractory bladder cancer. Patients with tumors with high risk features such as lymphovascular invasion and varying histology are good candidates for cystectomy. Patient comorbidities, age, and willingness are also important factors in the decision. Dr. Bagrodia also recommends getting a CT scan to check for nodal metastases. Both Dr. Clinton and Dr. Pietzak agree that it is beneficial to introduce the idea of cystectomy early and explain that the procedure does not prevent patients from living a fulfilling life. Finally, the doctors discuss recent BCG and gemcitabine clinical trials as well as new research about non-BCG therapies.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes

🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Other episodes from BackTable Urology

Transcribed and ready to explore now

Ep. 213 Dual Physician Households: Managing Parenthood and Careers with Dr. Katie Amin and Dr. Petar Bajic

04 Feb 2025

BackTable Urology

Ep. 212 Expanding Her Scope with SWIU: Dr. Catherine deVries on Navigating Challenges for Sustainable Global Impact

31 Jan 2025

BackTable Urology

Ep. 211 Mentorship and Growth Through the Society of Women in Urology with Dr. Simone Thavaseelan and Dr. Akanksha Mehta

28 Jan 2025

BackTable Urology

Ep. 210 Personalizing ADT Across the Prostate Cancer Spectrum with Dr. Rana McKay

21 Jan 2025

BackTable Urology

Ep. 207 Integrating Clinical Trials into Routine Urology Practice with Dr. Behfar Ehdaie

31 Dec 2024

BackTable Urology

BackTable Urology

Ep. 64 Management of BCG-Refractory NMIBC with Dr. Timothy Clinton and Dr. Eugene Pietzak

This episode hasn't been transcribed yet

Other episodes from BackTable Urology

Ep. 213 Dual Physician Households: Managing Parenthood and Careers with Dr. Katie Amin and Dr. Petar Bajic

Ep. 212 Expanding Her Scope with SWIU: Dr. Catherine deVries on Navigating Challenges for Sustainable Global Impact

Ep. 211 Mentorship and Growth Through the Society of Women in Urology with Dr. Simone Thavaseelan and Dr. Akanksha Mehta

Ep. 210 Personalizing ADT Across the Prostate Cancer Spectrum with Dr. Rana McKay

Ep. 207 Integrating Clinical Trials into Routine Urology Practice with Dr. Behfar Ehdaie

Ep. 206 Biochemical Recurrence: Insights from AUA/ASTRO/SUO Guidelines with Dr. Todd Morgan

Sign in to Audioscrape

Share this moment